BioNexus Gene Lab Corp (BGLC) Q1 2024 Annual Earnings
BGLC·Reported May 15, 2024·Before market open
BioNexus Gene Lab Corp reported Q1 2024 revenue of $2.4M (+0.2% YoY). Diluted EPS came in at $-0.18 (-277.3% YoY).
Revenue
$2.4M
Diluted EPS
$-0.18
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about BioNexus Gene Lab Corp's Q1 2024 earnings report.
BioNexus Gene Lab Corp (BGLC) reported Q1 2024 earnings on May 15, 2024 before market open.
BioNexus Gene Lab Corp reported revenue of $2.4M and diluted EPS of $-0.18 for Q1 2024.
Compared to the same quarter a year prior, revenue grew 0.2% from $2.4M a year earlier and diluted EPS declined 277.3% from $-0.05.
You can read the 10-K periodic report (0001477932-24-002151) directly on SEC EDGAR. The filing index links above go to sec.gov.